ΠΠΎΠΌΠ°ΡΠ½Ρ ΡΡΠΎΡΡΠ½ΠΊΠ°4559 β’ TYO
add
Zeria Pharmaceutical Co Ltd
ΠΠ°ΠΊΡΠΈΡΡΡ ΠΏΠΎΠΏΠ΅Ρ. Π΄Π½Ρ
2Β 288,00Β Β₯
ΠΡΠ°ΠΏΠ°Π·ΠΎΠ½ ΡΡΠ½ Π·Π° Π΄Π΅Π½Ρ
2Β 297,00Β Β₯ - 2Β 325,00Β Β₯
ΠΡΠ°ΠΏΠ°Π·ΠΎΠ½ ΡΡΠ½ Π·Π° ΡΡΠΊ
1Β 878,00Β Β₯ - 2Β 378,00Β Β₯
Π ΠΈΠ½ΠΊΠΎΠ²Π° ΠΊΠ°ΠΏΡΡΠ°Π»ΡΠ·Π°ΡΡΡ
115,83Β ΠΌΠ»ΡΠ΄ JPY
Π‘Π΅Ρ. ΠΎΠ±ΡΡΠ³
91,75Β ΡΠΈΡ.
ΠΠΎΠ΅ΡΡΡΡΡΠ½Ρ ΡΡΠ½Π°/ΠΏΡΠΈΠ±ΡΡΠΎΠΊ
14,02
ΠΠΈΠ²ΡΠ΄Π΅Π½Π΄Π½ΠΈΠΉ ΠΏΡΠΈΠ±ΡΡΠΎΠΊ
2,08%
ΠΡΠ½ΠΎΠ²Π½Π° Π±ΡΡΠΆΠ°
TYO
ΠΠΎΠ²ΠΈΠ½ΠΈ ΡΠΈΠ½ΠΊΡ
Π€ΡΠ½Π°Π½ΡΠΎΠ²Ρ Π΄Π°Π½Ρ
ΠΠ²ΡΡ ΠΏΡΠΎ ΡΡΠ½Π°Π½ΡΠΎΠ²Ρ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΈ
ΠΠΎΡ
ΡΠ΄
Π§ΠΈΡΡΠΈΠΉ Π΄ΠΎΡ
ΡΠ΄
| (JPY) | Π³ΡΡΠ΄. 2025β―Ρ.info | ΠΠΌΡΠ½Π° Π·Π° ΡΡΠΊ |
|---|---|---|
ΠΠΎΡ
ΡΠ΄ | 24,12Β ΠΌΠ»ΡΠ΄ | 7,90% |
ΠΠΏΠ΅ΡΠ°ΡΡΠΉΠ½Ρ Π²ΠΈΡΡΠ°ΡΠΈ | 12,82Β ΠΌΠ»ΡΠ΄ | 1,12% |
Π§ΠΈΡΡΠΈΠΉ Π΄ΠΎΡ
ΡΠ΄ | 3,82Β ΠΌΠ»ΡΠ΄ | 76,31% |
ΠΠ°ΡΠΆΠ° ΡΠΈΡΡΠΎΠ³ΠΎ ΠΏΡΠΈΠ±ΡΡΠΊΡ | β | β |
ΠΡΠΈΠ±ΡΡΠΎΠΊ Π½Π° Π°ΠΊΡΡΡ | β | β |
EBITDA | 6,81Β ΠΌΠ»ΡΠ΄ | 20,05% |
ΠΡΠ΅ΠΊΡΠΈΠ²Π½Π° ΡΡΠ°Π²ΠΊΠ° ΠΏΠΎΠ΄Π°ΡΠΊΡ | β | β |
ΠΡΡ
Π³Π°Π»ΡΠ΅ΡΡΡΠΊΠΈΠΉ Π±Π°Π»Π°Π½Ρ
ΠΠ°Π³Π°Π»ΡΠ½Π° Π²Π°ΡΡΡΡΡΡ Π°ΠΊΡΠΈΠ²ΡΠ²
ΠΠ°Π³Π°Π»ΡΠ½Π° ΡΡΠΌΠ° Π·ΠΎΠ±ΠΎΠ²βΡΠ·Π°Π½Ρ
| (JPY) | Π³ΡΡΠ΄. 2025β―Ρ.info | ΠΠΌΡΠ½Π° Π·Π° ΡΡΠΊ |
|---|---|---|
ΠΠΎΡΡΠ²ΠΊΠΎΠ²Ρ ΠΉ ΠΊΠΎΡΠΎΡΠΊΠΎΡΡΡΠΎΠΊΠΎΠ²Ρ Π²ΠΊΠ»Π°Π΄ΠΈ | 24,15Β ΠΌΠ»ΡΠ΄ | -1,48% |
ΠΠ°Π³Π°Π»ΡΠ½Π° Π²Π°ΡΡΡΡΡΡ Π°ΠΊΡΠΈΠ²ΡΠ² | 166,22Β ΠΌΠ»ΡΠ΄ | 6,16% |
ΠΠ°Π³Π°Π»ΡΠ½Π° ΡΡΠΌΠ° Π·ΠΎΠ±ΠΎΠ²βΡΠ·Π°Π½Ρ | 70,05Β ΠΌΠ»ΡΠ΄ | -1,81% |
ΠΠ°Π³. ΡΡΠΌΠ° Π²Π»Π°ΡΠ½. ΠΊΠ°ΠΏΡΡΠ°Π»Ρ | 96,18Β ΠΌΠ»ΡΠ΄ | β |
Π¦ΠΈΡΠΊΡΠ»ΡΡΡΡ Π°ΠΊΡΡΡ | 44,08Β ΠΌΠ»Π½ | β |
P/B ΠΊΠΎΠ΅ΡΡΡΡΡΠ½Ρ | 1,05 | β |
Π Π΅Π½ΡΠ°Π±Π΅Π»ΡΠ½ΡΡΡΡ Π°ΠΊΡΠΈΠ²ΡΠ² | 7,58% | β |
Π Π΅Π½ΡΠ°Π±Π΅Π»ΡΠ½ΡΡΡΡ ΠΊΠ°ΠΏΡΡΠ°Π»Ρ | 9,16% | β |
ΠΡΠΎΡΠΎΠ²ΠΈΠΉ ΠΏΠΎΡΡΠΊ
Π§ΠΈΡΡΠ° Π·ΠΌΡΠ½Π° Π·Π°Π»ΠΈΡΠΊΡ Π³ΠΎΡΡΠ²ΠΊΠΈ
| (JPY) | Π³ΡΡΠ΄. 2025β―Ρ.info | ΠΠΌΡΠ½Π° Π·Π° ΡΡΠΊ |
|---|---|---|
Π§ΠΈΡΡΠΈΠΉ Π΄ΠΎΡ
ΡΠ΄ | 3,82Β ΠΌΠ»ΡΠ΄ | 76,31% |
ΠΠΎΡΡΠ²ΠΊΠ° Π²ΡΠ΄ ΠΎΠΏΠ΅ΡΠ°ΡΡΠΉ | β | β |
ΠΠΎΡΡΠ²ΠΊΠ° Π²ΡΠ΄ ΡΠ½Π²Π΅ΡΡΠΈΡΡΠΉ | β | β |
ΠΠΎΡΡΠ²ΠΊΠ° Π²ΡΠ΄ ΡΡΠ½Π°Π½ΡΡΠ²Π°Π½Π½Ρ | β | β |
Π§ΠΈΡΡΠ° Π·ΠΌΡΠ½Π° Π·Π°Π»ΠΈΡΠΊΡ Π³ΠΎΡΡΠ²ΠΊΠΈ | β | β |
ΠΡΠ»ΡΠ½ΠΈΠΉ Π³ΡΠΎΡΠΎΠ²ΠΈΠΉ ΠΏΠΎΡΡΠΊ | β | β |
ΠΠ½ΡΠΎΡΠΌΠ°ΡΡΡ
Zeria Shinyaku KΕgyΕ KK is a Japanese drug manufacturer that obtained Tillotts Pharma AG.
In 1955, the Japanese Kisaku Ibu, former Yamanouchi Seiyaku executive opened a new pharmaceutical company in Tokyo under the name Zeria YakushΕ Kenkyusho. In 1970, this company becomes Zeria Shinyaku Zeria Shinyaku KK.
In 1975, it built a new factory in Kumagaya in Saitama prefecture, before the main factory in Tsukuba which was constructed by Takenaka Corporation in 1988.
In 2009, the company obtained Switzerland company Tillotts Pharma AG, and began operating internationally through a large network of subsidiaries,
It manufactures and sells pharmaceuticals in Sweden, Ireland, UK, Czech Republic, Spain, Germany, France, Italy, Vietnam and Denmark. The drug itself is developed in Switzerland, Tillotts Parma.
The company owns a 6.63% share of Asuka Seiyaku, also a pharmaceutical company, other than its subsidiaries.
The main shareholder of the company is the company itself, the present president Mitsuhiro Ibu, Mitsubishi UFJ Financial Group, Custody Bank of Japan, Morinaga Milk Industry, SMBC, Mizuho Bank, Risona Bank, Aioi Nissay Dowa Insurance as of March 2023. Wikipedia
ΠΠ΅Π½Π΅ΡΠ°Π»ΡΠ½ΠΈΠΉ Π΄ΠΈΡΠ΅ΠΊΡΠΎΡ
ΠΠ°ΡΠ° Π·Π°ΡΠ½ΡΠ²Π°Π½Π½Ρ
22 Π³ΡΡΠ΄. 1955β―Ρ.
ΠΠ΅Π±-ΡΠ°ΠΉΡ
ΠΡΠ»ΡΠΊΡΡΡΡ ΠΏΡΠ°ΡΡΠ²Π½ΠΈΠΊΡΠ²
1Β 746